Serum Brain-derived Neurotrophic Factor Levels among Euthymic Adolescents with Bipolar Disorder Type I

Binici, Nagihan Cevher; Resmi, Halil; Ellıdokuz, Hülya

doi:10.5152/npa.2015.8832

Cited by 9 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is possible that our patients were inadequate lithium responders as lithium did not recover GDS, and it is known that excellent lithium responders are associated with normal blood BDNF levels (Rybakowski 2014). In another study with euthymic adolescents with bipolar disorder, a lower BDNF level was detected in their blood after taking lithium (Cevher et al 2016). The variations in the BDNF gene promoter region affect the expression of BDNF and its role in various neuropsychiatric disorders.…”

Section: Discussionmentioning

confidence: 82%

Blood and cerebrospinal fluid biomarker changes in patients with HIV-associated neurocognitive impairment treated with lithium: analysis from a randomised placebo-controlled trial

et al. 2023

View full text Add to dashboard Cite

HIV-associated neurocognitive disorders (HAND) persist in the era of antiretroviral therapy (ART). Thus, ART does not completely halt or reverse the pathological processes behind HAND. Adjuvant mitigating treatments are, therefore, prudent. Lithium treatment is known to promote neuronal brain–derived neurotrophic factors (BDNF). Lithium is also an inhibitor of glycogen synthase kinase-3 beta (GSK-3-β). We analyzed biomarkers obtained from participants in a randomized placebo-controlled trial of lithium in ART-treated individuals with moderate or severe HAND. We assayed markers at baseline and 24 weeks across several pathways hypothesized to be affected by HIV, inflammation, or degeneration. Investigated biomarkers included dopamine, BDNF, neurofilament light chain, and CD8 + lymphocyte activation (CD38 + HLADR +). Alzheimer’s Disease (AD) biomarkers included soluble amyloid precursor protein alpha and beta (sAPPα/β), Aβ38, 40, 42, and ten other biomarkers validated as predictors of mild cognitive impairment and progression in previous studies. These include apolipoprotein C3, pre-albumin, α1-acid glycoprotein, α1-antitrypsin, PEDF, CC4, ICAM-1, RANTES, clusterin, and cystatin c. We recruited 61 participants (placebo = 31; lithium = 30). The age baseline mean was 40 (± 8.35) years and the median CD4 + T-cell count was 498 (IQR: 389–651) cells/μL. Biomarker concentrations between groups did not differ at baseline. However, both groups’ blood dopamine levels decreased significantly after 24 weeks (adj. p < 002). No other marker was significantly different between groups, and we concluded that lithium did not confer neuroprotection following 24 weeks of treatment. However, the study was limited in duration and sample size.

show abstract

Section: Discussionmentioning

confidence: 82%

Blood and cerebrospinal fluid biomarker changes in patients with HIV-associated neurocognitive impairment treated with lithium: analysis from a randomised placebo-controlled trial

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Seventeen studies have investigated the circulating levels of BDNF in BD patients during acute episodes compared with HC, and most of them have shown decreased BDNF circulating levels in BD patients during acute episodes when compared with HC. Only Barbosa et al (2010) [ 51 ] and Poletti et al (2017) [ 52 ] showed higher BDNF circulating levels in BD patients during acute episodes, while Binici et al (2016) [ 53 ], Ameele et al (2017) [ 54 ], and Skibinska et al (2021) [ 55 ] observed no significant difference in BDNF circulating levels between acute episodes of BD patients and HC. Most studies [ 44 , 56 , 57 , 58 , 59 , 60 ] have investigated BDNF serum levels during a depressive episode, while Tramontina et al (2009) [ 40 ], Machado-Vieira et al (2007) [ 61 ], and Oliveira et al (2009) [ 59 ] have included BD patients in a manic phase; only Piccinni et al (2014) [ 60 ] have included 19 mixed state patients, while Tunca et al (2014) [ 62 ] and Yoshimura et al (2006) [ 63 ] included both manic and depressive episodes.…”

Section: Resultsmentioning

confidence: 99%

“…The majority of studies included adult patients (18–65 years), while others also included adolescents [ 53 ]. Moreover, most studies recruited chronic and medicated patients, and only a few included first-onset drug-naive patients [ 44 , 45 , 57 , 59 , 61 ].…”

Section: Discussionmentioning

confidence: 99%

Can Brain-Derived Neurotrophic Factor Be Considered a Biomarker for Bipolar Disorder? An Analysis of the Current Evidence

De Felice,

Luciano,

Boiano

et al. 2023

Brain Sciences

View full text Add to dashboard Cite

Brain-derived neurotrophic factor (BDNF) plays a key role in brain development, contributing to neuronal survival and neuroplasticity. Previous works have found that BDNF is involved in several neurological or psychiatric diseases. In this review, we aimed to collect all available data on BDNF and bipolar disorder (BD) and assess if BDNF could be considered a biomarker for BD. We searched the most relevant medical databases and included studies reporting original data on BDNF circulating levels or Val66Met polymorphism. Only articles including a direct comparison with healthy controls (HC) and patients diagnosed with BD according to international classification systems were included. Of the 2430 identified articles, 29 were included in the present review. Results of the present review show a reduction in BDNF circulating levels during acute phases of BD compared to HC, which increase after effective therapy of the disorders. The Val66Met polymorphism was related to features usually associated with worse outcomes. High heterogeneity has been observed regarding sample size, clinical differences of included patients, and data analysis approaches, reducing comparisons among studies. Although more studies are needed, BDNF seems to be a promising biomarker for BD.

show abstract

“…Results obtained in different studies concerning the BDNF level in adolescents with mood disorders are inconsistent. Lack of differences in the group of euthymic as well as symptomatic patients with bipolar disorder compared to the control group was detected [ 36 , 37 , 38 , 39 , 40 ]. Correlations with amygdala volume and duration of the medication were reported [ 37 , 41 ] and lack of relationship with hippocampal volume in adolescents with bipolar disorder was found [ 41 , 42 ].…”

Section: Discussionmentioning

confidence: 99%

Elevated Epidermal Growth Factor (EGF) as Candidate Biomarker of Mood Disorders—Longitudinal Study in Adolescent and Young Adult Patients

Skibińska

Kapelski

Dmitrzak‐Węglarz

et al. 2021

JCM

View full text Add to dashboard Cite

Bipolar disorder (BD) is a chronic mental disorder that affects more than 1% of the population worldwide. Over 65% of patients experience early onset of the disease. Most cases of juvenile bipolar disorder begin with a depressed mood episode, and up to 50% of youth initially diagnosed with major depression go onto developing a BD. Our study aimed to find biomarkers of diagnosis conversion in young patients with mood disorders. We performed a two-year follow-up study on 79 adolescent patients diagnosed with MDD or BD, with a detailed clinical assessment at five visits. We monitored diagnosis change from MDD to BD. The control group consisted of 31 healthy youths. According to the neurodevelopmental and neuroimmunological hypotheses of mood disorders, we analyzed serum levels of brain-derived neurotrophic factor (BDNF), proBDNF, epidermal growth factor (EGF), migration inhibitory factor (MIF), stem cell factor (SCF), and correlations with clinical factors. We detected a significant disease-dependent increase in EGF level in MDD and BP patients at baseline exacerbation of depressive or hypomanic/manic episodes as well as in euthymic state compared to healthy controls. No potential biological predictors of disease conversion were found. Replication studies on a larger cohort of patients are needed.

show abstract

Serum Brain-derived Neurotrophic Factor Levels among Euthymic Adolescents with Bipolar Disorder Type I

Cited by 9 publications

References 19 publications

Blood and cerebrospinal fluid biomarker changes in patients with HIV-associated neurocognitive impairment treated with lithium: analysis from a randomised placebo-controlled trial

Blood and cerebrospinal fluid biomarker changes in patients with HIV-associated neurocognitive impairment treated with lithium: analysis from a randomised placebo-controlled trial

Can Brain-Derived Neurotrophic Factor Be Considered a Biomarker for Bipolar Disorder? An Analysis of the Current Evidence

Elevated Epidermal Growth Factor (EGF) as Candidate Biomarker of Mood Disorders—Longitudinal Study in Adolescent and Young Adult Patients

Contact Info

Product

Resources

About